Gwo-Yaw Ho

8PUBLICATIONS

78CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumoursPredictive and prognostic markersCancer genetics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|May 27, 2026

Assessment of pH-Responsive Ionisable Lipid Nanoparticles as Cisplatin Delivery Vehicles for Treating Cisplatin-Resistant Ovarian Cancer.

|Dec 27, 2024

Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer.

Laura R Moffitt, Nazanin Karimnia, Amy L Wilson

|Nov 29, 2023

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

Gwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim

|Oct 07, 2022

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.

Gwo Yaw Ho, Elizabeth L Kyran, Justin Bedo

|Nov 18, 2021

Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1-/- mice.

Jun T Low, Gwo-Yaw Ho, Mark Scott

|Jul 29, 2021

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

Ksenija Nesic, Olga Kondrashova, Rachel M Hurley

Pageof 2

Frequent Collaborators

Matthew J Wakefield

Clare L Scott

Anna DeFazio

Scott H Kaufmann

Chin Wee Tan

Olga Kondrashova

Justin Bedo

Hasan B Mirza

Cassandra J Vandenberg

1 joint publications

Andrew Farrell

Frequent Collaborators

Matthew J Wakefield

Clare L Scott

Anna DeFazio

Scott H Kaufmann